For research use only
| Cat No. | ABC-SC0021T |
| Product Type | Human iPSCs |
| Cell Type | Induced Pluripotent Stem Cell |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Fibroblast |
| Disease | Niemann Pick Type C |
| Storage | Liquid Nitrogen |
HighQC™ Human IPSC With Niemann Pick Type C Mutation provides a disease-specific stem cell model for NPC1-related pathogenesis and therapy development.
HighQC™ Human iPSC From Fibroblasts With Niemann Pick Type C-Female Donor is an induced pluripotent stem cell line reprogrammed from fibroblasts of an 8-year-old female patient diagnosed with Niemann-Pick Type C (NPC). The cell line was generated via episomal reprogramming using a proprietary mix of vectors, containing OCT4, SOX2, KLF4, p53 antisense, and EBNA-1. The cell line was validated for pluripotency based on classical colony morphology, alkaline phosphatase expression, and robust expression of key pluripotency markers including SSEA-4. The cell line is capable of differentiating into neural stem cells and functional neurons, making it especially suited for modeling neurodegenerative aspects of NPC. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.
| Product Code | HighQC™ Human IPSC From Fibroblasts With Niemann Pick Type C-Female Donor, Human iPSC-Fib-NPC-F, hIPSC-Fib-NPC-F, Human Female Donor iPSC Niemann Pick Fibroblasts |
| Species | Human |
| Cat.No | ABC-SC0021T |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Induced Pluripotent Stem Cell |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Fibroblast |
| Disease | Niemann Pick Type C |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
HighQC™ Human iPSC From Fibroblasts With Niemann Pick Type C-Female Donor serves as a physiologically relevant in vitro model for studying Niemann-Pick Type C disease’s mechanisms, including disrupted cholesterol transport and lysosomal dysfunction, and candidate compounds. Furthermore, the isogenic cell line enables mechanistic studies of Niemann-Pick Type C disease’s pathogenesis and validation of genetic correction strategies targeting the NPC1/NPC2 gene, supporting target identification and therapeutic development for this lysosomal storage disorder.
When you publish your research, please cite our product as "AcceGen Biotech Cat.# XXX-0000". In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).